These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1604509)

  • 1. Abrogation of islet immunogenicity using an anti-MHC class I monoclonal antibody.
    Munn SR; Marjoribanks C
    Transplant Proc; 1992 Jun; 24(3):1038-9. PubMed ID: 1604509
    [No Abstract]   [Full Text] [Related]  

  • 2. Pretreatment of rat pancreatic islets with MHC I-A monoclonal antibody: in-vitro and in-vivo effects on islet antigenicity.
    Flesch BK; Bretzel RG; Otto DA; Ernst-Schlegel M; Federlin K
    Horm Metab Res; 1991 Aug; 23(8):357-61. PubMed ID: 1794836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MHC class II antigen expression on the various cells of normal and activated isolated pancreatic islets.
    Ulrichs K; Müller-Ruchholtz W
    Diagn Immunol; 1985; 3(1):47-55. PubMed ID: 3922662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of intra-islet endothelial cells in islet allo-immunity.
    Bharat A; Saini D; Benshoff N; Goodman J; Desai NM; Chapman WC; Mohanakumar T
    Transplantation; 2007 Nov; 84(10):1316-23. PubMed ID: 18049117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of reduction of class II antigens on the survival of pancreatic allografts.
    Spillenaar-Bilgen EJ; Bouwman E; de Bruin RW; Marquet RL; Jeekel J
    Transplant Proc; 1989 Feb; 21(1 Pt 1):515-6. PubMed ID: 2495619
    [No Abstract]   [Full Text] [Related]  

  • 6. Rat pancreatic islet pretreatment with anti-MHC class II monoclonal antibodies and culture: in vitro MLIC test response does not predict islet allograft survival.
    Bretzel RG; Flesch BK; Brennenstuhl G; Greiner I; Hering BJ; Woehrle M; Federlin K
    Acta Diabetol; 1993; 30(1):49-56. PubMed ID: 8329731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic effects of islet cell surface antibodies.
    Hehmke B; Kohnert KD; Dietz H; Zühlke H
    Acta Biol Med Ger; 1982; 41(12):1117-22. PubMed ID: 6765153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Masking donor major histocompatibility complex class I antigens on allogeneic islets.
    Munn SR; Marjoribanks C
    Transplant Proc; 1992 Dec; 24(6):2857. PubMed ID: 1465973
    [No Abstract]   [Full Text] [Related]  

  • 9. Studies of privileged sites and islet transplantation.
    Barker CF; Markmann JF; Posselt AM; Naji A
    Transplant Proc; 1991 Aug; 23(4):2138-42. PubMed ID: 1871831
    [No Abstract]   [Full Text] [Related]  

  • 10. Human islet preparations and the expression of MHC antigens.
    Swift SM; Thirdborough SM; London NJ; Cahill M; James RF
    Transplant Proc; 1992 Jun; 24(3):1029. PubMed ID: 1604507
    [No Abstract]   [Full Text] [Related]  

  • 11. Intrathymic transplantation of rat perinatal islets, devoid of class II bearing cells, does not induce donor-specific tolerance.
    Moore WV; Moyer C; Pan F; Donaldson D; Forster J; Kover K
    Transplant Proc; 1995 Dec; 27(6):3200. PubMed ID: 8539912
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of monoclonal and polyclonal anti-pancreatic cell antibodies for purification and identification of porcine islet cells.
    Tze WJ; Cheung SS; Tai J
    Transplant Proc; 1992 Dec; 24(6):2837-9. PubMed ID: 1465964
    [No Abstract]   [Full Text] [Related]  

  • 13. Modulation of MHC class I antigen decreases pancreatic islet immunogenicity.
    Stock PG; Ascher NL; Chen S; Bumgardner GL; Field MJ; Sutherland DE
    J Surg Res; 1989 Apr; 46(4):317-21. PubMed ID: 2649742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of class I+, class II- hepatocytes.
    Almond PS; Bumgardner GL; Chen S; Platt J; Payne WD; Matas AJ
    Transplant Proc; 1991 Feb; 23(1 Pt 1):108-9. PubMed ID: 1899298
    [No Abstract]   [Full Text] [Related]  

  • 15. Standardization of the human mixed lymphocyte islet coculture.
    Swift SM; Rose SH; London NJ; James RF
    Transplant Proc; 1994 Apr; 26(2):732. PubMed ID: 8171630
    [No Abstract]   [Full Text] [Related]  

  • 16. Diabetic BB/PFD rats reject MHC incompatible islet grafts, but do not destroy MHC compatible islet grafts.
    Mathieu C; Waer M; Kuttler B; Hahn HJ; Bouillon R
    Transplant Proc; 1994 Apr; 26(2):718-9. PubMed ID: 8171623
    [No Abstract]   [Full Text] [Related]  

  • 17. Islets deficient in cell-surface class I MHC (B2M-/-) induce unresponsiveness in allogeneic recipients.
    Ninova D; Marjoribanks C; Munn SR
    Transplant Proc; 1995 Dec; 27(6):3195. PubMed ID: 8539909
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of humoral immunity in pancreatic islet allo- and xenograft rejection.
    Ahn M; Sohn C; Chang E; Chu G; DeMatteo RP; Barker CF; Markmann JF
    Transplant Proc; 1996 Apr; 28(2):840-1. PubMed ID: 8623428
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro model for cellular cytotoxicity against rat Langerhans' islets. Protective effect of mouse interferon on rat target cells.
    Farkas G; Pusztai R; Mándi Y; Béládi I
    Transplantation; 1983 Nov; 36(5):583-4. PubMed ID: 6195787
    [No Abstract]   [Full Text] [Related]  

  • 20. Isolation of functional MHC class I-deficient islet cells.
    Osorio RW; Ascher NL; Jaenisch R; Natuzzi ES; Freise CE; Roberts JP; Stock PG
    Transplant Proc; 1993 Feb; 25(1 Pt 2):968-9. PubMed ID: 8442283
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.